While we were unable to compare TGFβ3 expression in the tumor tissue with that found in circulation, our observations collectively are consistent with our findings here that the treatment of micrometastatic, liver-limited mCRC with BA may have promoted tumor hyperprogression for the patients on this study. The gene discussed is TGFB3; the disease is neoplasm.